Skip to content

DOC

Healthpeak Properties

NYSEReal EstateReit - Healthcare FacilitiesSnapshot 2026-05-08

$19.64-0.10%
Close 2026-05-08 · 1-day change
The bottom line

As of May 8, 2026, DOC has a mixed analyst signal with a composite score of 2.3 and a medium confidence level of 70.9. The score is influenced by various factors, including a favorable outlook if next-quarter guidance is raised, but it could decline if the real estate sector trend weakens. The top drivers affecting the score include macroeconomic factors such as rates, growth, labor, and inflation. This analysis is provisional.

Composite +2.3as of 2026-05-08

Price

Daily closes from AlphaVantage. Earnings/event dots are placed inline.

Close 2026-05-08
Daily closes. Scroll over the chart to zoom; click a range to reset.
EarningsMaterial event

Factor signals

Read top-to-bottom: thesis (is this a strong company over a 1–3 year hold), watch flags (has something changed worth re-reading), and position context (how violent might the path be). Each pill is a parallel diagnostic — never aggregated into a single score.

L1

Thesis

is this a strong company over a 1–3 year hold?
F1 · Recent financial performance
strong
Top 10% of real estate cohort
Why this rank
  • Direction share
    1.00
  • Slope (norm)
    0.58
  • Bonus
    0.00
Operating income, last 4 quarters ($M)
234065146
F2 · Value
expensive
Most expensive 10% of real estate cohort
Why this rank
Price
$19.64
TTM EPS
$0.01
Earnings yield
0.1%
P/E (TTM)
1964.0

Trailing four: 2024-Q3, 2025-Q1, 2025-Q2, 2025-Q3

F3 · Earnings quality
robust
Top 30% cash conversion in real estate cohort
Why this rank
TTM NI ($M)
243
TTM CFO ($M)
1,071
CFO/NI
4.40

Joint read: strong + robust historically delivered 80%+ NI-grew rate over T+1y in IT 2024–26 (small N).

L2

Watch

has something changed worth re-reading?
F4 · Management stability
Insufficient data
No score yet
Earnings setup · pre-print positioning
forward-looking
bullishEPS revised -3.3% / 30d, n=6for period ending 2026-06-30
Why this setup
Consensus revisions

EPS estimate $0.05 → $0.05 (-3.3% / 30d). 0 raised, 0 cut, 6 covering analysts.

Rating actions

0 upgrades, 0 downgrades / 30d, 1 maintained. 50% of analysts rate Buy.

Price target activity

2 PT revisions / 30d. Avg target 5.8% above current price.

Material events

1 positive, 0 negative / 30d. See F4 management tile for the event list.

F4 · Management deep-dive — recent events, stated priorities, guidance track record
1

Recent 8-K events

No recent events recorded.

2

Stated priorities

3 priorityies extracted from earnings transcripts (as of 2026-05-08).

  1. 1.Reaffirming 2026 NOI growth guidancegrowthmixed39% progress
    5/5: We are reaffirming full year 2026 Total Same-Store Cash (Adjusted) NOI growth in the range of (1.0%) – 1.0%.
    Why this status

    Stated in 2 of last 2 quarters. Healthpeak reaffirmed its 2026 NOI growth guidance range of (1.0%) to 1.0%. Despite the reaffirmation, financials show a net income of $321.9M in 2025-Q4, up from a loss of $117.1M in 2025-Q3, indicating some positive trajectory but limited progress towards the upper end of the guidance range.

  2. 2.Updating 2026 EPS guidancegrowthmixed39% progress
    5/5: We are updating the following guidance ranges for full year 2026: • Diluted earnings per common share from $0.34 – $0.38 to $0.46 – $0.50.
    Why this status

    Stated in 2 of last 2 quarters. Healthpeak updated its 2026 EPS guidance to $0.46 – $0.50. The financials show a net income increase from $6.7M in 2025-Q1 to $321.9M in 2025-Q4, suggesting a positive trajectory towards achieving the updated EPS guidance.

  3. 3.Reaffirming 2026 FFO guidancegrowthmixed39% progress
    5/5: Diluted Nareit FFO per share from $1.70 – $1.74 to $1.68 – $1.72.
    Why this status

    Stated in 2 of last 2 quarters. Healthpeak reaffirmed its 2026 FFO guidance range of $1.68 to $1.72. Despite the reaffirmation, revenue decreased from $705.9M in 2025-Q3 to $693.7M in 2025-Q4, indicating limited progress towards achieving the FFO guidance.

3

Guidance track record

Insufficient guidance history for this ticker.

L3

Position context

how violent might the path be while I hold it?
Risk profile · realized
backward-looking
moderateworst 12m loss −17%, typical day ±0.9%
Why this risk level

Recent vol — 30d annualized 53%; 252d 29%.

Drawdown — Max 1y −17%. Bad day move −2%.

Beta to sector ETF (XLRE) 1.16 over 1y.

Liquidity — score 100/100.

Sub-scores — vol 52/100, drawdown 66/100, beta 84/100, earnings vol .

Sector regime
headwind-3.1%sector vs S&P 500, 60d

via XLRE

Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive — historically, headwind regimes have averaged stronger forward returns than tailwind.

AI cycle regime · market-wide
2-axis classifier
HeatingManiaSquallCrisisEarnings →Mood ↑
HeatingE +0.13 · M +0.71
Single-axisCHASEz +2.97+1.285d

Context label only — describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.

Not investment advice. As of 2026-05-08.

3

What changed

The most important moves since the prior daily snapshot.

  1. No material changes since the prior snapshot.

No material changes since the prior snapshot.

as of 2026-05-08

4

Management scorecard

How management runs the business — capital, margins, balance sheet, and how reliably they guide and deliver.

Composite26.7 / 100
Capital allocation11
Earnings discipline49
Margin discipline36
Balance sheet21
Guidance credibility
Post-call reaction32
as of 2026-05-08
4

What management is focused on

Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.

  • #1

    Reaffirming 2026 NOI growth guidance

    GrowthNew since 2026-05-05

    Healthpeak is reaffirming its full year 2026 Total Same-Store Cash (Adjusted) NOI growth guidance in the range of (1.0%) to 1.0%.

    Mixed

    Stated in 2 of last 2 quarters. Healthpeak reaffirmed its 2026 NOI growth guidance range of (1.0%) to 1.0%. Despite the reaffirmation, financials show a net income of $321.9M in 2025-Q4, up from a loss of $117.1M in 2025-Q3, indicating some positive trajectory but limited progress towards the upper end of the guidance range.

    39%
    CEO/CFO:We are reaffirming full year 2026 Total Same-Store Cash (Adjusted) NOI growth in the range of (1.0%) – 1.0%.
    Multiple sourcesSource dated 2026-05-05Stated 2 of last 8 quartersFirst seen 2026-05-05
    Show history (2)
    • 2026-Q1Multiple sources

      Total Merger-Combined Same-Store Cash (Adjusted) NOI growth of (1%) – 1%

    • 2025-Q4Multiple sources

      Total Merger-Combined Same-Store Cash (Adjusted) NOI growth of (1%) – 1%

  • #2

    Updating 2026 EPS guidance

    GrowthNew since 2026-05-05

    Healthpeak updated its full year 2026 EPS guidance from $0.34 – $0.38 to $0.46 – $0.50.

    Mixed

    Stated in 2 of last 2 quarters. Healthpeak updated its 2026 EPS guidance to $0.46 – $0.50. The financials show a net income increase from $6.7M in 2025-Q1 to $321.9M in 2025-Q4, suggesting a positive trajectory towards achieving the updated EPS guidance.

    39%
    CEO/CFO:We are updating the following guidance ranges for full year 2026: • Diluted earnings per common share from $0.34 – $0.38 to $0.46 – $0.50.
    Multiple sourcesSource dated 2026-05-05Stated 2 of last 8 quartersFirst seen 2026-05-05
    Show history (2)
    • 2026-Q1Multiple sources

      Diluted earnings per common share from $0.34 – $0.38 to $0.46 – $0.50

    • 2025-Q4Multiple sources

      Diluted earnings per common share from $0.34 – $0.38

  • #3

    Reaffirming 2026 FFO guidance

    GrowthNew since 2026-05-05

    Healthpeak reaffirmed its full year 2026 FFO per share guidance in the range of $1.68 to $1.72.

    Mixed

    Stated in 2 of last 2 quarters. Healthpeak reaffirmed its 2026 FFO guidance range of $1.68 to $1.72. Despite the reaffirmation, revenue decreased from $705.9M in 2025-Q3 to $693.7M in 2025-Q4, indicating limited progress towards achieving the FFO guidance.

    39%
    CEO/CFO:Diluted Nareit FFO per share from $1.70 – $1.74 to $1.68 – $1.72.
    Multiple sourcesSource dated 2026-05-05Stated 2 of last 8 quartersFirst seen 2026-05-05
    Show history (2)
    • 2026-Q1Multiple sources

      Diluted Nareit FFO per share from $1.70 – $1.74 to $1.68 – $1.72

    • 2025-Q4Multiple sources

      Diluted Nareit FFO per share of $1.70 – $1.74

as of 2026-05-08
5

How this stock is priced

Two ways to read price: against peers in the same business, and against the company's own history.

Compared to peers
96higher = cheaper

Looks cheaper than most peers in the same business.

Compared to its own history
3higher = cheaper

Richer than its own typical valuation.

P/E
77.5x
EV/EBITDA
10.0x
FCF yield
8.3%

P/E over the last 5 years

64 monthly points
fairas of 2026-05-08
7

How this compares

A side-by-side read on composite, valuation, and risk versus peers.

StockCompositeValuationRisk
DOC
Healthpeak Properties
+2.3fairmoderate
WELL
Welltower
+7.9expensivelow
PLD
Prologis
+10fulllow
EQIX
Equinix
+22fairmoderate
AMT
American Tower
+18fairmoderate
8

Risk — how this stock moves

What a normal day looks like, what a bad day looks like, and the worst the last year has thrown at it.

A typical day
How much price usually moves either way.
0.9%
A bad day (95th %ile)
A rough but not unusual down day.
-2.1%
Worst 12-month loss
Deepest peak-to-trough drop in the last year.
-17.1%
Earnings-day move
How much price usually moves on earnings day.
moderateas of 2026-05-08
9

What could change this view

Conditional scenarios — if X happens, the score would shift by about Y points. These are not predictions.

Upside triggers
  • If next-quarter guidance is raised (currently LOWERED as of 2026-05-05)+16 pts
  • If real_estate sector trend rises from +0.00 into 'improving' (>= +0.20)+5.0 pts
  • If next-quarter EPS surprise repeats current direction (latest surprise +234.9% on 2026-03-31)+2.4 pts
Downside triggers
  • If rates state reverses from -0.37 (negative) to +0.37 (positive)-8.0 pts
  • If real_estate sector trend falls from +0.00 into 'weakening' (<= -0.20)-5.0 pts
10

Material updates

Recent SEC 8-K filings ranked by likely impact, confidence, and recency.

  1. 2026-05-054d agoItem 2.02

    Results of Operations and Financial Condition. On May 5, 2026, Healthpeak Properties, Inc., a Maryland corporation (“Healthpeak”), issued a press release setting forth its financial results for the first quarter and three months ended March 31, 2026. The press release refers to the Discussion and Reconciliation of Non-GAAP Financial Measures, which is available in the Investor Relations section of Healthpeak’s website, free of charge, at http://ir.healthpeak.com/quarterly-results . The press…

    earnings preannouncementpositivescore 66
11

Score history

The composite score, snapshot by snapshot. The dotted line at zero separates leaning-positive from leaning-negative.

60 snapshots
Data freshness · As of 2026-05-08 · Macro 2026-05-08 · Sector 2026-05-07 · Fundamentals 2026-02-03 · Price 2026-05-07 · Generated 2026-05-08 · Spec 2.3

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.